Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 2
2002 6
2003 6
2004 9
2005 12
2006 30
2007 31
2008 57
2009 67
2010 69
2011 97
2012 132
2013 162
2014 192
2015 221
2016 244
2017 287
2018 354
2019 470
2020 549
2021 595
2022 726
2023 698
2024 812
2025 15

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,181 results

Results by year

Filters applied: . Clear all
Page 1
Multiple Signaling Roles of CD3ε and Its Application in CAR-T Cell Therapy.
Wu W, Zhou Q, Masubuchi T, Shi X, Li H, Xu X, Huang M, Meng L, He X, Zhu H, Gao S, Zhang N, Jing R, Sun J, Wang H, Hui E, Wong CC, Xu C. Wu W, et al. Among authors: meng l. Cell. 2020 Aug 20;182(4):855-871.e23. doi: 10.1016/j.cell.2020.07.018. Epub 2020 Jul 29. Cell. 2020. PMID: 32730808 Free article.
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.
Jiang Q, Li Z, Qin Y, Li W, Xu N, Liu B, Zhang Y, Meng L, Zhu H, Du X, Chen S, Liang Y, Hu Y, Liu X, Song Y, Men L, Chen Z, Niu Q, Wang H, Lu M, Yang D, Zhai Y, Huang X. Jiang Q, et al. Among authors: meng l. J Hematol Oncol. 2022 Aug 18;15(1):113. doi: 10.1186/s13045-022-01334-z. J Hematol Oncol. 2022. PMID: 35982483 Free PMC article. Clinical Trial.
O-GlcNAc has crosstalk with ADP-ribosylation via PARG.
Li J, Liu X, Peng B, Feng T, Zhou W, Meng L, Zhao S, Zheng X, Wu C, Wu S, Chen X, Xu X, Sun J, Li J. Li J, et al. Among authors: meng l. J Biol Chem. 2023 Nov;299(11):105354. doi: 10.1016/j.jbc.2023.105354. Epub 2023 Oct 17. J Biol Chem. 2023. PMID: 37858678 Free PMC article.
Editorial: Non-coding RNAs in Reproductive Biology.
Meng L, Teerds K, Tang Z, Zuo B, Hong L. Meng L, et al. Front Cell Dev Biol. 2021 Jun 24;9:712467. doi: 10.3389/fcell.2021.712467. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34249951 Free PMC article. No abstract available.
Validation of the imatinib-therapy failure model.
Zhang X, Gale RP, Liu B, Huang J, Zhang Y, Du X, Weng J, Li W, Xu N, Liu X, Chen C, Lin H, Li G, Liang R, Liu Z, Wang X, Zhang Y, Han Y, Liu C, Hu J, Lin L, Yang W, Liu Z, Meng L, Tu C, Zheng C, Zhou Z, Bai Y, Qiu H, Chen S, Li F, Guo J, Liu Z, Sun H, Zhou L, Feng R, Sun X, Huang X, Jiang Q. Zhang X, et al. Among authors: meng l. Leukemia. 2023 May;37(5):1166-1169. doi: 10.1038/s41375-023-01875-3. Epub 2023 Mar 27. Leukemia. 2023. PMID: 36973351 No abstract available.
Imatinib compared with second-generation tyrosine kinase-inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase.
Yang S, Zhang X, Gale RP, Du X, Chen CY, Weng JY, Huang J, Li F, Zeng Y, Xiao Z, Hu JD, Yang LJ, Liu ZG, Li GH, Sun XL, Yang W, Feng R, Han YQ, Jing Y, Xu N, Liu XL, Liu ZF, Wang XD, Wu SX, Liang R, Zhang YL, Yang YF, Zhu HL, Pan L, Meng L, Zhao YH, Yi H, Liu YL, Zhang WH, Zheng YJ, Zhou ZP, Chen SN, Qiu HY, Li WM, Jia ZL, Bai YL, Lin LE, Liu BC, Liu CS, Luo JM, Meng JX, Sun ZQ, Zhang YQ, Huang XJ, Jiang Q. Yang S, et al. Among authors: meng l. Am J Hematol. 2023 Jul;98(7):E183-E186. doi: 10.1002/ajh.26943. Epub 2023 May 2. Am J Hematol. 2023. PMID: 37128776 Free article. No abstract available.
5,181 results